Relive the excitement of the Patriots’ path to their fourth Super Bowl Championship with “Pumped”, a special commemorative book from The Boston Globe. Order now.

FDA warns of another compounding pharmacy recall

Repackaged injections of Avastin cost about $50, compared with $1,950 for Lucentis.

Genentech Inc. via AP

Repackaged injections of Avastin cost about $50, compared with $1,950 for Lucentis.

WASHINGTON — The Food and Drug Administration is warning doctors that a compounding pharmacy is recalling dozens of lots of the Roche drug Avastin after receiving reports of eye infections among patients.

The FDA said Wednesday that Clinical Specialties of Martinez, Ga., has received five reports of eye infections from physicians who used the drug to treat macular degeneration.

Continue reading below

The compounding pharmacy is recalling 40 lots of Avastin distributed in Georgia, Louisiana, South Carolina, and Indiana since Dec. 18, the FDA said in an online posting.

Avastin is approved as a cancer drug but is structurally similar to Lucentis, another Roche drug approved for macular degeneration. For years, compounding pharmacies have repackaged Avastin into small vials for use by eye doctors who prescribe it off-label, or without FDA approval. Repackaged injections of Avastin cost about $50, compared with $1,950 for Lucentis.

A call placed to Clinical Specialties’ lead pharmacist, Austin Gore, was not immediately returned Wednesday.

Swiss drug maker Roche has tried to discourage doctors from using Avastin for such unapproved uses.

However, groups like the American Academy of Ophthalmologists say there is no detectable difference in outcomes for patients. More than half the injections given for macular generation in the United States are Avastin, according to the group.

Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com